Recruiting
Phase 2

FDA Approved Drugs

Sponsor:

American Society of Clinical Oncology

Code:

NCT02693535

Conditions

Lymphoma, Non-Hodgkin

Multiple Myeloma

Advanced Solid Tumors

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Sunitinib

Temsirolimus

Trastuzumab and Pertuzumab

Vemurafenib and Cobimetinib

Olaparib

Study Details

Brief summary:

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.

NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress.

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Conditions

Lymphoma, Non-Hodgkin

Multiple Myeloma

Advanced Solid Tumors

Study ID

NCT02693535

Start date

Mar 14, 2016

Status verified date

Aug, 2026

Completion date

Dec 31, 2028

Anticipated

Primary completion date

Dec 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • 12 years of age or older (\*Restrictions apply. Not all therapies are available for patients <18)
  • Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated (except under the circumstance in which the TAPUR arm is designed to provide additional evidence to support an existing FDA indication).
  • Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria)
  • Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion/exclusion criteria specified in the protocol appendix for each agent will take precedence for this and all inclusion criteria:

1. Absolute neutrophil count ≥ 1500 µl
2. Hemoglobin ≥ 9.0 g/dl
3. Platelets ≥ 75,000/µl
4. Total bilirubin < 2.0 mg/ dl, except in patients with Gilbert's Syndrome
5. Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) < 2.5 x institutional upper limit of normal (ULN) (or < 5 x ULN in patients with known hepatic metastases)
6. Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
  • Patients must have disease that can be objectively measured by physical, laboratory or radiographic exam (per RECIST v1.1 for solid tumor, Lugano criteria for non-Hodgkin lymphoma or International Myeloma Working Group criteria for multiple myeloma).
  • Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited or New York State accredited (for labs offering services to residents of NY) laboratory. Labs that have registered the test with the NIH Genetic Testing Registry or that provide a report that has been designated as optimized for TAPUR participation are preferred, but not required. The genomic or IHC test used to qualify a patient for participation in TAPUR may have been performed on any specimen of the patient's tumor obtained at any point during the patient's care at the discretion of the patient's treating physician. Genomic assays performed on cell-free DNA in plasma ("liquid biopsies") will also be acceptable if the genomic analysis is performed in a laboratory that meets the criteria described above.
  • Ability to understand and the willingness to sign a written informed consent/assent document.
  • Have a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit based on the criteria described in protocol.
  • For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.
  • Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study or if she is the partner of a male participant in this study and becomes pregnant while he is participating in this study, she should inform her or her partner's treating physician immediately as well as her obstetrician. Female study patients who become pregnant must immediately discontinue treatment with any study therapy. Male patients should avoid impregnating a female partner. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and for a specified amount of time the last dose of study treatment, or completely abstain from sexual intercourse.

Note: TAPUR does not explicitly exclude any type of solid tumor, but the patient must have measurable and evaluable disease per RECIST v1.1.

Exclusion Criteria:

  • Patients whose disease is not measurable or cannot be assessed by radiographic imaging or physical examination (e.g., elevated serum tumor marker only) are not eligible
  • Patients with primary brain tumors or new, untreated or progressive leptomeningeal metastases are excluded
  • Patients with previously treated brain metastases or previously treated leptomeningeal disease are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 1 months prior to registration. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month prior to study enrollment.
  • Patients with known progressive brain metastases are eligible but additional eligibility criteria apply.

Note: there are additional exclusion criteria that may apply

Study Design

Enrollment

4200 participants

Anticipated

Allocation

Non randomized

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

other: Group 5 (CSF1R,PDGFR,VEGFR)

Participants receive sunitinib - dosage, frequency and duration per label; acceptable genomic matches include CSF1R, PDGFR, VEGFR1/2/3, KIT, FLT-3, RET, FGFR1/2/3, VHL amplifications or mutations

other: Group 6 (mTOR, TSC)

Participants receive temsirolimus - dosage, frequency and duration per label; acceptable genomic matches include mTOR, TSC1/2, AKT1 mutations

other: Group 8 (ERBB2)

Participants receive trastuzumab and pertuzumab - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations

other: Group 9 (BRAF V600E/D/K/R)

Participants receive vemurafenib and cobimetinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600E/D/K/R mutations

other: Group 14 (BRCA1/2; ATM)

Participants receive olaparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 inactivating mutations; ATM mutations or deletions

other: Group 16 (MSI-H, high mutational load and others)

Participants receive nivolumab and ipilimumab - dosage, frequency and duration per label; acceptable genomic matches include MSI high status, high tumor mutational burden, MLH1, MSH2/6, PMS2, EPCAM mutations, specific POLE or POLD1 mutations, BRCA1/2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1/2/3/4/5, PCNA, RPA1/2/3/4, and SSBP1 loss of function mutations

other: Group 17 (CDKN2A, CDK4, CDK6)

Participants receive abemaciclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications, CDKN2B loss or mutation

other: Group 19 (BRCA1/2, PALB2)

Participants receive talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 and PALB2 mutations

other: Group 21 (BRCA1/2, PALB2, ATM, and others)

Participants receive atezolizumab plus talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic mutations in BRCA1/2, PALB2, ATM, ATR, CHEK2, FANCA, RAD51C, NBN, MLH1, MRE11A, CDK12; positive genomic instability score reported on the Myriad MyChoice CDx test; or Genomic Loss of Heterozygosity (LOH) Score above threshold as reported on a FoundationOne CDx test or another qualifying test for TAPUR with MTB approval

other: Group 24 (ERBB2)

Participants receive tucatinib plus trastuzumab SC - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations

other: Group 25

Participants receive futibatinib- dosage, frequency and duration per label; acceptable genomic matches include FGFR 1,2,3,4 fusion (or other rearrangement) or mutation

other: Group 26 (BRAF V600 E mutation )

Participants receive Dabrafenib plus Trametinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600 E mutation .

other: Group 27 (ERBB2 amplification, ERBB2 (HER2) IHC2+ or IHC3+ overexpression)

Participants receive Fam-trastuzumab deruxtecan-nxki (ENHERTU®) - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification, For NSCLC Only-ERBB2 (HER2) IHC2+ or IHC3+ overexpression without ERBB2 amplification)

Interventions

Sunitinib

drug

Temsirolimus

drug

Trastuzumab and Pertuzumab

drug

Vemurafenib and Cobimetinib

drug

Olaparib

drug

Nivolumab and Ipilimumab

drug

Abemaciclib

drug

Talazoparib

drug

Atezolizumab and Talazoparib

drug

Tucatinib plus Trastuzumab Subcutaneous (SC)

drug

Futibatinib

drug

Dabrafenib plus Trametinib

Drug

Fam-Trastuzumab Deruxtecan-Nxki (TDxD)

Drug

Primary outcome measure

  • Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria [ Time Frame: Assessed at 16 weeks of treatment ]

Central Contacts and Locations

Central contacts

Laurie Smith, MA

www.tapur.orgtapur@asco.org

Locations

University of Alabama at Birmingham Comprehensive Cancer Center

Recruiting

Birmingham, Alabama, United States, 35294

Contacts

Kun Yuan

205-644-2584kunyuan@uabmc.edu

Principal Investigator:

Mehmet Akce, MD

Cancer Treatment Centers of America-Phoenix

Recruiting

Phoenix, Arizona, United States, 85338

Contacts

Alex Lizzul

602-872-5654alizzul@coh.org

Principal Investigator:

Sagun Shrestha, MD

Sutter Auburn

Recruiting

Auburn, California, United States, 95602

Contacts

Kirsten Babski

916-878-4990BabskiK@sutterhealth.org

Principal Investigator:

Nitin Rohatgi, MD

Sutter Alta Bates

Recruiting

Berkeley, California, United States, 94705

Contacts

Christopher Tang

510-204-3428Christopher.Tang@sutterhealth.org

Principal Investigator:

Nitin Rohatgi, MD

The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate

Recruiting

Los Angeles, California, United States, 90025

Contacts

Teri Mata

310-231-2115tmata@theangelesclinic.org

Principal Investigator:

Omid Hamid, MD

Kaiser Permanente - Oakland Medical Center

Recruiting

Oakland, California, United States, 94611

Contacts

Desiree Goldstein

desiree.goldstein@kp.org

Principal Investigator:

Jennifer M Suga, MD

Sutter Palo Alto Medical Foundation: Palo Alto

Recruiting

Palo Alto, California, United States, 94301

Contacts

clinicaltrials@pamf.org

Kaiser Permanente - Roseville Medical Center

Recruiting

Roseville, California, United States, 95661

Contacts

Desiree Goldstein

desiree.goldstein@kp.org

Principal Investigator:

Jennifer M Suga, MD

Sutter Roseville

Recruiting

Roseville, California, United States, 95661

Contacts

Kirsten Babski

916-878-4990BabskiK@sutterhealth.org

Principal Investigator:

Nitin Rohatgi, MD

Kaiser Permanente - Sacramento Medical Center

Recruiting

Sacramento, California, United States, 95814

Contacts

Desiree Goldstein

desiree.goldstein@kp.org

Principal Investigator:

Jennifer M Suga, MD

Sutter Sacramento

Recruiting

Sacramento, California, United States, 95816

Contacts

SIMR@sutterhealth.org

Principal Investigator:

Nitin Rohatgi, MD

Kaiser Permanente - South San Francisco Medical Center

Recruiting

San Francisco, California, United States, 94080

Contacts

Desiree Goldstein

desiree.goldstein@kp.org

Principal Investigator:

Jennifer M Suga, MD

California Pacific Medical Center Research Institute

Recruiting

San Francisco, California, United States, 94115

Contacts

415-600-1654clinicalresearch@sutterhealth.org

Principal Investigator:

Nitin Rohatgi, MD

Kaiser Permanente - San Francisco Medical Center

Recruiting

San Francisco, California, United States, 94115

Contacts

Desiree Goldstein

desiree.goldstein@kp.org

Principal Investigator:

Jennifer M Suga, MD

Sutter Cancer Research Consortium

Recruiting

San Francisco, California, United States, 94115

Contacts

Laurel Brechtel

415-600-1654BrechtLa@cpmcri.org

Principal Investigator:

Stacy D'Andre, MD

Kaiser Permanente - San Jose Medical Center

Recruiting

San Jose, California, United States, 95119

Contacts

Desiree Goldstein

desiree.goldstein@kp.org

Principal Investigator:

Jennifer M Suga, MD

Kaiser Permanente - San Leandro Medical Center

Recruiting

San Leandro, California, United States, 94577

Contacts

Desiree Goldstein

desiree.goldstein@kp.org

Principal Investigator:

Jennifer M Suga, MD

Sutter Sansum Clinic

Recruiting

Santa Barbara, California, United States, 93105

Contacts

Selina Perez

831-458-5837Selina.Perez@sutterhealth.org

Principal Investigator:

Nitin Rohatgi, MD

Kaiser Permanente - Santa Clara Medical Center

Recruiting

Santa Clara, California, United States, 95051

Contacts

Desiree Goldstein

desiree.goldstein@kp.org

Principal Investigator:

Jennifer M Suga, MD

Sutter Palo Alto Medical Foundation: Santa Cruz

Recruiting

Santa Cruz, California, United States, 95065

Contacts

clinicaltrials@pamf.org

Sutter Palo Alto Medical Foundation: Fremont

Recruiting

Santa Cruz, California, United States, 994538

Contacts

clinicaltrials@pamf.org

Sutter Palo Alto Medical Foundation: Sunnyvale

Recruiting

Sunnyvale, California, United States, 94086

Contacts

clinicaltrials@pamf.org

Kaiser Permanente - Vallejo Medical Center

Recruiting

Vallejo, California, United States, 94589

Contacts

Desiree Goldstein

desiree.goldstein@kp.org

Principal Investigator:

Jennifer M. Suga, MD

Kaiser Permanente - Walnut Creek Medical Center

Recruiting

Walnut Creek, California, United States, 94596

Contacts

Desiree Goldstein

desiree.goldstein@kp.org

Principal Investigator:

Jennifer M Suga, MD

Saint Vincent's Medical Center (SVMC)

Recruiting

Bridgeport, Connecticut, United States, 06606

Contacts

860-972-4700CancerResearchSupport@hhchealth.org

Principal Investigator:

Wylie Hosmer, MD

Hartford Hospital

Recruiting

Hartford, Connecticut, United States, 06102

Contacts

860-972-4700CancerResearchSupport@hhchealth.org

Principal Investigator:

Wylie Hosmer, MD

Midstate Medical Center (MSMC)

Recruiting

Meriden, Connecticut, United States, 06451

Contacts

860-972-4700CancerResearchSupport@hhchealth.org

Principal Investigator:

Wylie Hosmer, MD

The Hospital of Central Connecticut (HOCC) Cancer Center

Recruiting

New Britain, Connecticut, United States, 06053

Contacts

8609724700CancerResearchSupport@hhchealth.org

Principal Investigator:

Wylie Hosmer, MD

William W. Backus Hospital

Recruiting

Norwich, Connecticut, United States, 06360

Contacts

860-972-4700CancerResearchSupport@hhchealth.org

Principal Investigator:

Wylie Hosmer, MD

Charlotte Hungerford

Recruiting

Torrington, Connecticut, United States, 06790

Contacts

860-972-4700CancerResearchSupport@hhchealth.org

Principal Investigator:

Wylie Hosmer, MD

Windham Hospital (WH)

Recruiting

Willimantic, Connecticut, United States, 06226

Contacts

860-972-4700CancerResearchSupport@hhchealth.org

Principal Investigator:

Wylie Hosmer, MD

University of Miami/Sylvester Cancer Institute - Aventura

Recruiting

Aventura, Florida, United States, 33180

Contacts

Carolina Troche, BS

305-243-1481cxt582@med.miami.edu

Principal Investigator:

Carmen Calfa, MD

University of Miami/Sylvester Cancer Institute - Lennar

Recruiting

Coral Gables, Florida, United States, 33146

Contacts

Carolina Troche, BS

305-243-1481cxt582@med.miami.edu

Principal Investigator:

Carmen Calfa, MD

University of Miami/Sylvester Cancer Institute - Deerfield Beach

Recruiting

Deerfield Beach, Florida, United States, 33442

Contacts

Carolina Troche, BS

305-243-1481cxt582@med.miami.edu

Principal Investigator:

Carmen Calfa, MD

Holy Cross Hospital

Recruiting

Fort Lauderdale, Florida, United States, 33308

Contacts

7347123671MCRCwebsitecontactform@trinity-health.org

Principal Investigator:

Zdenka Segota, MD

University of Florida Health

Recruiting

Gainesville, Florida, United States, 32610

Contacts

Anna Kukulka, RN, BSN

352-293-2551akukulka@ufl.edu

Principal Investigator:

Thomas George, MD

University of Miami Sylvester Comprehensive Cancer Center

Recruiting

Miami, Florida, United States, 33136

Contacts

Carolina Troche, BS

305-243-1481cxt582@med.miami.edu

Principal Investigator:

Carmen Calfa, MD

University of Miami/Sylvester Cancer Institute - Alex's Place

Recruiting

Miami, Florida, United States, 33136

Contacts

Carolina Troche, BS

305-243-1481cxt582@med.miami.edu

Principal Investigator:

Carmen Calfa, MD

University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building

Recruiting

Miami, Florida, United States, 33136

Contacts

Carolina Troche, BS

305-243-1481cxt582@med.miami.edu

Principal Investigator:

Carmen Calfa, MD

University of Miami/Sylvester Cancer Institute - Kendall

Recruiting

Miami, Florida, United States, 33176

Contacts

Carolina Troche, BS

305-243-1481cxt582@med.miami.edu

Principal Investigator:

Carmen Calfa, MD

University of Miami/Sylvester Cancer Institute - Sole Mia

Recruiting

Miami, Florida, United States, 33181

Contacts

Carolina Troche, BS

305-243-1481cxt582@med.miami.edu

Principal Investigator:

Carmen Calfa, MD

University of Miami/Sylvester Cancer Institute - Plantation

Recruiting

Plantation, Florida, United States, 33324

Contacts

Carolina Troche, BS

305-243-1481cxt582@med.miami.edu

Principal Investigator:

Carmen Calfa, MD

Cancer Treatment Centers of America - Atlanta

Recruiting

Atlanta, Georgia, United States, 30265

Contacts

Elizabeth McKoy, RN, BSN

770-400-7177emckoy@coh.org

Principal Investigator:

Bamidele Adesunloye, MD

Emory University Winship Cancer Institute

Recruiting

Atlanta, Georgia, United States, 30322

Contacts

Krystal Bagley

404-778-8670krystal.joi.bagley@emory.edu

Principal Investigator:

Olatunji Alese, MD

Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion

Recruiting

Savannah, Georgia, United States, 31405

Contacts

Stephanie Smith, RN, MSN, OCN

9128195723smiths1@sjchs.org

Principal Investigator:

Mark Taylor, MD

Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma Institute

Recruiting

Savannah, Georgia, United States, 31405

Contacts

Stephanie Smith, RN, MSN, OCN

19128195723smiths1@sjchs.org

Principal Investigator:

Mark Taylor, MD

Lewis Cancer & Research Pavilion

Recruiting

Savannah, Georgia, United States, 31405

Contacts

Stephanie Smith, RN, MSN, OCN

912-819-5723smiths1@sjchs.org

Principal Investigator:

Mark Taylor, MD

Summit Cancer Care

Recruiting

Savannah, Georgia, United States, 31405

Contacts

Stephanie Smith, RN, MSN, OCN

9128195723smiths1@sjchs.org

Principal Investigator:

Mark Taylor, MD

The Queen's Medical Center - POB I

Recruiting

Honolulu, Hawaii, United States, 96813

Contacts

Tim Kelleher

8086918582tkelleher@queens.org

Principal Investigator:

Jared Acoba, MD

The Queen's Medical Center - Punchbowl

Recruiting

Honolulu, Hawaii, United States, 96813

Contacts

Tim Kelleher

808 691-8582tkelleher@queens.org

Principal Investigator:

Jared Acoba, MD

The Queen's Medical Center - Kuakini

Recruiting

Honolulu, Hawaii, United States, 96817

Contacts

Tim Kelleher

8086918582tkelleher@queens.org

Principal Investigator:

Jared Acoba, MD

The Queen's Medical Center - West Oahu

Recruiting

‘Ewa Beach, Hawaii, United States, 96706

Contacts

Tim Kelleher

8086918582tkelleher@queens.org

Principal Investigator:

Jared Acoba, MD

Cancer Treatment Centers of America-Chicago

Recruiting

Chicago, Illinois, United States, 60099

Contacts

Office of Clinical Trials

847-731-1777CHIResearch@coh.org

Principal Investigator:

Evan Pisick, MD

Community Health Network (The University of Texas MD Anderson Cancer Center)

Recruiting

Indianapolis, Indiana, United States, 46250

Contacts

Kshipra Sharma, MPH, MS

713-745-8431Ksharma2@MDAnderson.org

Principal Investigator:

Funda Meric-Bernstam, MD

Harold Alfond Center for Cancer Care

Recruiting

Augusta, Maine, United States, 04330

Contacts

Sandra Neptune, BSN, RN

207-626-4811sandra.neptune@mainegeneral.org

Principal Investigator:

Lindsay Hathaway, MD

Jackson Laboratory - Maine Cancer Genomics Initiative

Recruiting

Augusta, Maine, United States, 04330

Contacts

Petra Helbig, CCRP

207-664-4659Petra.Helbig@jax.org

Principal Investigator:

Jens Rueter, MD

Waldo County General Hospital

Recruiting

Belfast, Maine, United States, 04915

Contacts

Jen - Dalton, MHA, BSN, RN

2072948291JDalton@mmc.org

Principal Investigator:

Roger Inhorn, MD

SMHC Cancer Care and Blood Disorders -Biddeford

Recruiting

Biddeford, Maine, United States, 04005

Contacts

Jen - Dalton

2072948291JDalton@mmc.org

Principal Investigator:

Roger Inhorn, MD

Northern Light Cancer Care

Recruiting

Brewer, Maine, United States, 04412

Contacts

Carla Mancini, MHA, BSN, RN

207-973-5581cmancini@northernlight.org

Principal Investigator:

Sarah Sinclair, MD

Raish Peavey Haskell Children's Cancer and Treatment Center

Recruiting

Brewer, Maine, United States, 04412

Contacts

Carla C Mancini, RN, BSN, OCN

2079735581cmancini@northernlight.org

Principal Investigator:

Sarah Sinclair, MD

MaineHealth Cancer Care -Brunswick

Recruiting

Brunswick, Maine, United States, 04011

Contacts

Jen - Dalton, MHA, BSN, RN

2072948291JDalton@mmc.org

Principal Investigator:

Roger Inhorn, MD

New England Cancer Specialist

Recruiting

Kennebunk, Maine, United States, 04043

Contacts

Patricia C Collins

2073033422collip@newecs.org

Principal Investigator:

Christian Thomas, MD

York Hopsital Oncology & Infusion Care in Kittery

Recruiting

Kittery, Maine, United States, 03904

Contacts

Brenda i Kiberd, RN

2073616115Brenda.Kiberd@yorkhospital.com

Principal Investigator:

Marilyn McLaughlin, MD

Stephens Memorial Hospital

Recruiting

Norway, Maine, United States, 04268

Contacts

Jen - Dalton, MHA, BSN, RN

2072948291JDalton@mmc.org

Principal Investigator:

Roger Inhorn, MD

Penobscot Bay Medical Center

Recruiting

Rockport, Maine, United States, 04856

Contacts

Jen - Dalton, MHA, BSN, RN

2072948291JDalton@mmc.org

Principal Investigator:

Roger Inhorn, MD

SMHC Cancer Care and Blood Disorders -Sandford

Recruiting

Sanford, Maine, United States, 04073

Contacts

Jen - Dalton, MHA, BSN, RN

2072948291JDalton@mmc.org

Principal Investigator:

Roger Inhorn, MD

Maine Children's Cancer Program

Recruiting

Scarborough, Maine, United States, 04074

Contacts

Jen - Dalton, MHA, BSN, RN

2072948291JDalton@mmc.org

Principal Investigator:

Roger Inhorn, MD

Maine Medical Partner's Women's Health

Recruiting

Scarborough, Maine, United States, 04074

Contacts

Jen - Dalton, MHA, BSN, RN

2072948291JDalton@mmc.org

Principal Investigator:

Roger Inhorn, MD

New England Cancer Specialist

Recruiting

Scarborough, Maine, United States, 04074

Contacts

Patricia Collins, BA, CCRC

207-303-3422collip@newecs.org

Principal Investigator:

Christian Thomas, MD

MaineHealth Cancer Care -South Portland

Recruiting

South Portland, Maine, United States, 04106

Contacts

Jen Dalton, MHA, BSN, RN

207-294-8291JDalton@mmc.org

Principal Investigator:

Roger Inhorn, MD

New England Cancer Specialist

Recruiting

Topsham, Maine, United States, 04086

Contacts

Patricia C Collins, BA, CCRC

12073033422collip@newecs.org

Principal Investigator:

Christian Thomas, MD

York Hospital Oncology & Infusion Care in Wells

Recruiting

Wells, Maine, United States, 04090

Contacts

Brenda Kiberd, RN

207-361-6115Brenda.Kiberd@yorkhospital.com

Principal Investigator:

Marilyn McLaughlin, MD

York Hospital Oncology & Infusion Care in York

Recruiting

York Village, Maine, United States, 03909

Contacts

Brenda i Kiberd, RN

2073616115Brenda.Kiberd@yorkhospital.com

Principal Investigator:

Marilyn McLaughlin, MD

Trinity Health Ann Arbor Hospital

Recruiting

Ann Arbor, Michigan, United States, 48106

Contacts

7347123671MCRCwebsitecontactform@trinity-health.org

Principal Investigator:

Elie Dib, MD

Henry Ford Health Saint John Hospital

Recruiting

Detroit, Michigan, United States, 48236

Contacts

7347123671MCRCwebsitecontactform@trinity-health.org

Principal Investigator:

Carrie Dul, MD

Genesys Hurley Cancer Institute

Recruiting

Flint, Michigan, United States, 48503

Contacts

7347123671MCRCwebsitecontactform@trinity-health.org

Principal Investigator:

Paul Adams, MD

Cancer Research Consortium of West Michigan

Recruiting

Grand Rapids, Michigan, United States, 49503

Contacts

Connie Szczepanek, RN

616-391-1230crcwm-regulatory@crcwm.org

Principal Investigator:

Kathleen J. Yost, MD

University of Michigan Health - Sparrow Lansing

Recruiting

Lansing, Michigan, United States, 48912

Contacts

7347123671MCRCwebsitecontactform@trinity-health.org

Principal Investigator:

Gordan Srkalovic, MD

Trinity Health Livonia Hospital

Recruiting

Livonia, Michigan, United States, 48154

Contacts

7347127251MCRCwebsitecontactform@trinity-health.org

Principal Investigator:

Amit Mohindra, MD

Trinity Health Oakland Hospital

Recruiting

Pontiac, Michigan, United States, 48341

Contacts

7347123671MCRCwebsitecontactform@trinity-health.org

Principal Investigator:

Julie Goodman, MD

MyMichigan Medical Center Saginaw

Recruiting

Saginaw, Michigan, United States, 48601

Contacts

7347123671MCRCwebsitecontactform@trinity-health.org

Principal Investigator:

Nicholas Damico, MD

Michigan Cancer Research Consortium

Recruiting

Traverse City, Michigan, United States, 48341

Contacts

Beth LaVasseur, RN, MS

734-712-7251Beth.LaVasseur@stjoeshealth.org

877-590-5995

Principal Investigator:

Philip Stella, MD

Henry Ford Health Warren Hospital

Recruiting

Warren, Michigan, United States, 48093

Contacts

7347123671MCRCwebsitecontactform@trinity-health.org

Principal Investigator:

Carrie Dul, MD

University of Nebraska Medical Center

Recruiting

Omaha, Nebraska, United States, 68198

Contacts

Micki Bethea, BS

402-559-8011mbethea@unmc.edu

Principal Investigator:

Alissa Marr, MD

NH Oncology - Hematology, PA

Recruiting

Concord, New Hampshire, United States, 03103

Contacts

Ali Fleury

6033146888A.Fleury@nhoh.com

Principal Investigator:

Michael Buff, MD

Solinsky Center for Cancer Care

Recruiting

Manchester, New Hampshire, United States, 03103

Contacts

Ali Fleury, BA, CCRP

603-314-6888A.Fleury@nhoh.com

Principal Investigator:

Michael Buff, MD

New England Cancer Specialist

Recruiting

Portsmouth, New Hampshire, United States, 03801

Contacts

Patricia C Collins, BA, CCRC

2073033422collip@newecs.org

Principal Investigator:

Christian Thomas, MD

Lovelace Medical Center - Saint Joseph Square

Recruiting

Albuquerque, New Mexico, United States, 87102

Contacts

Leslie Byatt

(505) -925-0366lpbyatt@salud.unm.edu

Principal Investigator:

Bernard Tawfik, MD

Presbyterian Kaseman Hospital

Recruiting

Albuquerque, New Mexico, United States, 87110

Contacts

Monique Robertson, RN

(505)- 559-6100mrobertso2@phs.org

Principal Investigator:

Bernard Tawfik, MD

The University of New Mexico Comprehensive Cancer Center

Recruiting

Albuquerque, New Mexico, United States, 87131

Contacts

Sheri Westgate, RN-BSN, OCN

(505) -925-0383swestgate@salud.unm.edu

Principal Investigator:

Bernard Tawfik, MD

Memorial Medical Center

Recruiting

Las Cruces, New Mexico, United States, 88011

Contacts

Kim Hoffman, RN

(575)- 556-6545kim.hoffman@lpnt.net

Principal Investigator:

Bernard Tawfik, MD

Presbyterian Rust Medical Center

Recruiting

Rio Rancho, New Mexico, United States, 87124

Contacts

Andrea Yost

(505) -253-7878ayost3@phs.org

Principal Investigator:

Bernard Tawfik, MD

Northwell Health Monter Cancer Center

Recruiting

Lake Success, New York, United States, 11042

Contacts

Mary Agnes Templeton

516-734-8979mtempleton@northwell.edu

Principal Investigator:

Marina Frimer, MD

Northern Westchester Hospital

Recruiting

Mount Kisco, New York, United States, 10549

Contacts

Jemima Jacob, MPH

914-666-1366jjacob22@northwell.edu

Principal Investigator:

Marina Frimer, MD

Cohen Children's Medical Center

Recruiting

New Hyde Park, New York, United States, 11040

Contacts

Shreya Seepersaud

718-470-7146sseepersaud2@northwell.edu

Principal Investigator:

Marina Frimer, MD

Manhattan Eye, Ear, and Throat Hospital

Recruiting

New York, New York, United States, 10065

Contacts

Leila Nasr

lnasr@northwell.edu

Principal Investigator:

Marina Frimer, MD

Staten Island University Hospital

Recruiting

New York, New York, United States, 10305

Contacts

Sammi Ruan

718-226-1489sruan2@northwell.edu

Melissa McCarthy

718-226-1805mccarthy22@northwell.edu

Principal Investigator:

Marina Frimer, MD

Queens Cancer Center

Recruiting

Rego Park, New York, United States, 11374

Contacts

Harmandeep Kaur

718-412-0773hkaur37@northwell.edu

Principal Investigator:

Marina Frimer, MD

Phelps Hospital

Recruiting

Sleepy Hollow, New York, United States, 10591

Contacts

Barbara Turner, RN

914-269-1949Bturner1@northwell.edu

Shyrley Gomez

Sgomez21@northwell.edu

Principal Investigator:

Marina Frimer, MD

Lineberger Comprehensive Cancer Center

Recruiting

Chapel Hill, North Carolina, United States, 27599

Contacts

Emmie Cole

919-966-4432emmie_cole@med.unc.edu

Principal Investigator:

Shetal Patel, MD

Atrium Health's Levine Cancer Institute

Recruiting

Charlotte, North Carolina, United States, 28277

Contacts

Jenna Gregory, MS, RN

Jenna.Gregory@atriumhealth.org

Principal Investigator:

Kathryn F. Mileham, MD, FACP

Sanford Health- Bismarck

Recruiting

Bismarck, North Dakota, United States, 58501

Contacts

Peter Kurniali, MD

701-323-5741peter.kurniali@sanfordhealth.org

Principal Investigator:

Peter Kurniali, MD

Sanford Health- Fargo

Recruiting

Fargo, North Dakota, United States, 58122

Contacts

Anu Gaba, MD

701-234-6161anu.gaba@sanfordhealth.org

Principal Investigator:

Anu Gaba, MD

University of Cincinnati Medical Center

Recruiting

Cincinnati, Ohio, United States, 45219

Contacts

Kayla Webb, MSN, RN

513-584-0599webb2ka@ucmail.uc.edu

Principal Investigator:

Davendra Sohal, MD

Kettering Health

Recruiting

Kettering, Ohio, United States, 45429

Contacts

Allison Dymacek, BSN, RN

937-395-8367allison.dymacek@ketteringhealth.org

Principal Investigator:

Lex Leonhardt, DO

West Chester Hospital

Recruiting

West Chester, Ohio, United States, 45069

Contacts

Kayla Webb, MSN, RN

513-584-0599webb2ka@ucmail.uc.edu

Principal Investigator:

Trisha Wise-Draper, MD

Providence Health & Services

Recruiting

Portland, Oregon, United States, 97213

Contacts

Isa Ngirailemesang

971-358-2056Isa.Ngirailemesang@providence.org

Principal Investigator:

Evthokia Hobbs, MD

Lehigh Valley Hospital - Cedar Crest

Recruiting

Allentown, Pennsylvania, United States, 18103

Contacts

734-712-3671MCRCwebsitecontactform@trinity-health.org

Principal Investigator:

Maged Khalil, MD

Lehigh Valley Hospital- Muhlenberg

Recruiting

Bethlehem, Pennsylvania, United States, 18017

Contacts

7347127251MCRCwebsitecontactform@trinity-health.org

Principal Investigator:

Maged Khalil, MD

Pocono Medical Center

Recruiting

East Stroudsburg, Pennsylvania, United States, 18301

Contacts

7347127251MCRCwebsitecontactform@trinity-health.org

Principal Investigator:

Maged Khalil, MD

Lehigh Valley Hospital-Hazleton

Recruiting

Hazleton, Pennsylvania, United States, 18201

Contacts

7347127251MCRCwebsitecontactform@trinity-health.org

Principal Investigator:

Maged Khalil, MD

Fox Chase Cancer Center

Recruiting

Philadelphia, Pennsylvania, United States, 19111

Contacts

Fathima S Sheriff

215-728-4094fathima.sheriff@fccc.edu

Principal Investigator:

Margaret von Mehren, MD

SC Cancer Specialists at St. Joseph's/Candler Bluffton

Recruiting

Bluffton, South Carolina, United States, 29910

Contacts

Stephanie Smith, RN, MSN, OCN

19128195723smiths1@sjchs.org

Principal Investigator:

Mark Taylor, MD

St. Joseph's/Candler Smith

Recruiting

Bluffton, South Carolina, United States, 29910

Contacts

Stephanie Smith, RN, MSN, OCN

19128195723smiths1@sjchs.org

Principal Investigator:

Mark Taylor, MD

Summit Cancer Care at St. Josph's/Candler Bluffton

Recruiting

Bluffton, South Carolina, United States, 29910

Contacts

Stephanie Smith, RN, MSN, OCN

19128195723smiths1@sjchs.org

Principal Investigator:

Mark Taylor, MD

South Carolina Cancer Specialists

Recruiting

Hilton Head Island, South Carolina, United States, 29926

Contacts

Stephanie Smith, RN, MSN, OCN

19128195723smiths1@sjchs.org

Principal Investigator:

Mark Taylor, MD

Sanford Cancer Center Oncology Clinic and Pharmacy

Recruiting

Sioux Falls, South Dakota, United States, 57104

Contacts

Steven Powell, MD

605-328-8000steven.powell@sanfordhealth.org

Principal Investigator:

Steven Powell, MD

Tennessee Oncology - Nashville / Sarah Cannon Research Institute

Recruiting

Nashville, Tennessee, United States, 37203

Contacts

Ethan Trull

615-329-7274Ethan.Trull@SarahCannon.com

Principal Investigator:

Meredith McKean, MD, MPH

The University of Texas MD Anderson Cancer Center

Recruiting

Houston, Texas, United States, 77030

Contacts

Kshipra Sharma, MPH, MS

713-745-8431Ksharma2@MDAnderson.org

Principal Investigator:

Funda Meric-Bernstam, MD

Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center

Recruiting

Cedar City, Utah, United States, 84720

Contacts

Jake Kolu

435-705-1632Jake.Kolu@imail.org

Principal Investigator:

Ramya Thota, MD

Intermountain Healthcare

Recruiting

Salt Lake City, Utah, United States, 84107

Contacts

Tracy Taylor

801-507-3953tracy.taylor@imail.org

Principal Investigator:

Ramya Thota, M.D.

Dixie Regional Medical Center-River Road Campus

Recruiting

St. George, Utah, United States, 84770

Contacts

Jake Kolu

435-705-1632Jake.Kolu@imail.org

Principal Investigator:

Ramya Thota, MD

Inova Schar Cancer Institute

Recruiting

Fairfax, Virginia, United States, 22042

Contacts

Roxana Comfort, CRC

571-472-0628roxana.comfort@inova.org

Principal Investigator:

Timothy Cannon, MD

Northwest Medical Specialties

Recruiting

Bonney Lake, Washington, United States, 98391

Contacts

Jennifer Spokely

253-999-3701research@southsoundcare.org

Principal Investigator:

Frank Senecal, MD

Northwest Medical Specialties

Recruiting

Federal Way, Washington, United States, 98003

Contacts

Jennifer Spokely

253-999-3701research@southsoundcare.org

Principal Investigator:

Frank Senecal, MD

Northwest Medical Specialties

Recruiting

Gig Harbor, Washington, United States, 98332

Contacts

Jennifer Spokely

253-999-3701research@southsoundcare.org

Principal Investigator:

Frank Senecal, MD

Northwest Medical Specialties

Recruiting

Olympia, Washington, United States, 98502

Contacts

Jennifer Spokely

253-999-3701research@southsoundcare.org

Principal Investigator:

Frank Senecal, MD

Northwest Medical Specialties

Recruiting

Puyallup, Washington, United States, 98373

Contacts

Jennifer Spokely

253-999-3701reserch@southsoundcare.org

Principal Investigator:

Frank Senecal, MD

Swedish Cancer Institute

Recruiting

Seattle, Washington, United States, 98104

Contacts

Sidney Ching

206-386-3142sidney.ching@swedish.org

Principal Investigator:

Philip Gold, MD

Northwest Medical Specialties

Recruiting

Tacoma, Washington, United States, 98405

Contacts

Jennifer Spokely

253-999-3701reserch@southsoundcare.org

Principal Investigator:

Frank Senecal, MD

Aurora Cancer Care - Burlington

Recruiting

Burlington, Wisconsin, United States, 53105

Contacts

Michelle Toutloff, RN, CCRP

9204567880Michelle.Martin2@aah.org

Principal Investigator:

Antony Ruggeri, MD

Aurora Health Care - Germantown Health Center

Recruiting

Germantown, Wisconsin, United States, 53022

Contacts

Michelle Toutloff, RN, CCRP

9204567880Michelle.Martin2@aah.org

Principal Investigator:

Antony Ruggeri, MD

Aurora Cancer Care - Grafton

Recruiting

Grafton, Wisconsin, United States, 53024

Contacts

Michelle Toutloff, RN, CCRP

9204567880Michelle.Martin2@aah.org

Principal Investigator:

Antony Ruggeri, MD

Aurora BayCare Medical Center

Recruiting

Green Bay, Wisconsin, United States, 54311

Contacts

Michelle Toutloff, RN, CCRP

9204567880Michelle.Martin2@aah.org

Principal Investigator:

Antony Ruggeri, MD

Aurora Cancer Care - Kenosha South

Recruiting

Kenosha, Wisconsin, United States, 53142

Contacts

Michelle Toutloff, RN, CCRP

9204567880Michelle.Martin2@aah.org

Principal Investigator:

Antony Ruggeri, MD

Aurora Bay Area Medical Center

Recruiting

Marinette, Wisconsin, United States, 54143

Contacts

Michelle Toutloff, RN, CCRP

9204567880Michelle.Martin2@aah.org

Principal Investigator:

Antony Ruggeri, MD

Aurora Cancer Care Milwaukee

Recruiting

Milwaukee, Wisconsin, United States, 53209

Contacts

Michelle M Toutloff, RN, CCRP

9204567880Michelle.Martin2@aah.org

Principal Investigator:

Antony Ruggeri, MD

Aurora St. Luke's Medical Center

Recruiting

Milwaukee, Wisconsin, United States, 53215

Contacts

Michelle M Toutloff, RN, CCRP

9204567880Michelle.Martin2@aah.org

Principal Investigator:

Antony Ruggeri, MD

Aurora Sinai Medical Center

Recruiting

Milwaukee, Wisconsin, United States, 53223

Contacts

Michelle Toutloff, RN, CCRP

9204567880Michelle.Martin2@aah.org

Principal Investigator:

Antony Ruggeri, MD

Aurora West Allis Medical Center

Recruiting

Milwaukee, Wisconsin, United States, 53227

Contacts

Michelle Toutloff, RN, CCRP

9204567880Michelle.Martin2@aah.org

Principal Investigator:

Antony Ruggeri, MD

Vince Lombardi Cancer Clinic - Oshkosh

Recruiting

Oshkosh, Wisconsin, United States, 54904

Contacts

Michelle Toutloff, RN, CCRP

9204567880Michelle.Martin2@aah.org

Principal Investigator:

Antony Ruggeri, MD

Aurora Cancer Care - Racine

Recruiting

Racine, Wisconsin, United States, 53406

Contacts

Michelle Toutloff, RN, CCRP

9204567880Michelle.Martin2@aah.org

Principal Investigator:

Antony Ruggeri, MD

Vince Lombardi Cancer Center

Recruiting

Sheboygan, Wisconsin, United States, 53081

Contacts

Michelle Toutloff, RN, CCRP

9204567880Michelle.Martin2@aah.org

Principal Investigator:

Antony Ruggeri, MD

Aurora Medical Center in Summit

Recruiting

Summit, Wisconsin, United States, 53066

Contacts

Michelle Toutloff, RN, CCRP

9204567880Michelle.Martin2@aah.org

Principal Investigator:

Antony Ruggeri, MD

Vince Lombardi Cancer Clinic - Two Rivers

Recruiting

Two Rivers, Wisconsin, United States, 54241

Contacts

Michelle Toutloff, RN, CCRP

9204567880Michelle.Martin2@aah.org

Principal Investigator:

Antony Ruggeri, MD

Aurora Cancer Care - Milwaukee West

Recruiting

Wauwatosa, Wisconsin, United States, 53226

Contacts

Michelle Toutloff, RN, CCRP

920-456-7880Michelle.Martin2@aah.org

Principal Investigator:

Antony Ruggeri, MD

More Information

Sponsor

American Society of Clinical Oncology

Last update posted

Sep 1, 2026

Last verified

Aug, 2026

Keywords

  • cancer
  • off-label
  • precision medicine
  • targeted therapy

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-04. This information was provided to ClinicalTrials.gov by American Society of Clinical Oncology on 2026-09-01.